Top

Annals of Surgical Oncology

Published in:

01-05-2010 | Emerging Therapeutic Approaches to Hepatocellular Carcinoma

Intra-Arterial Therapies for Hepatocellular Carcinoma: Where Do We Stand?

Authors: Eleni Liapi, MD, Jean-Francois H. Geschwind, MD

Published in: Annals of Surgical Oncology | Issue 5/2010

Abstract

Purpose and Design

Intra-arterial therapies for unresectable hepatocellular carcinoma (HCC) consist of a catheter-based group of treatments where therapeutic and/or embolic agents are intra-arterially directed to target tumors. Here we review these therapies, which may be classified into embolotherapy/chemotherapy-based and radiotherapy-based treatments. Embolotherapy/chemotherapy-based treatments include transcatheter arterial embolization, transarterial chemoembolization, transcatheter arterial chemoeinfusion, and chemoembolization with drug-eluting beads. Radiotherapy-based treatments include radioembolization with yttrium-90 and injection of iodine-131-labeled lipiodol.

Results and Conclusion

Interpretation of the results of clinical trials as well as implementation of meta-analyses involving the efficacy of intra-arterial therapies for unresectable HCC has been challenging and difficult to perform. The levels of evidence for treatment recommendations in oncology provide a common framework to understand the current status of intra-arterial therapies for HCC. Here we use an evidence-based approach to critically review and comprehend the current role and future potential of intra-arterial therapies in unresectable HCC.

Gyves JW, Ziessman HA, Ensminger WD, et al. Definition of hepatic tumor microcirculation by single photon emission computerized tomography (SPECT). J Nucl Med. 1984;25:972–7.PubMed

Bierman HR, Byron RL Jr, Kelley KH, Grady A. Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo. J Natl Cancer Inst. 1951;12:107–31.PubMed

Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.CrossRefPubMed

Ramsey DE, Kernagis LY, Soulen MC, Geschwind J-FH. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002;13:211S–21.CrossRef

Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–64.CrossRefPubMed

Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10:2878–82.PubMed

Kim KW, Bae SK, Lee OH, et al. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res. 1998;58:348–51.PubMed

Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:1178–82.CrossRefPubMed

Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440(7088):1222–6.CrossRefPubMed

10.

Geschwind J-FH, Ramsey DE, van der Wal BCH, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol. 2003;26:111.CrossRefPubMed

11.

Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma—a randomized controlled trial. Gastroenterology. 1988;94:453–6.PubMed

12.

Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9.CrossRefPubMed

13.

Rand T, Loewe C, Schoder M, Schmook MT, et al. Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, lipiodol, and cyanoacrylate. Cardiovasc Intervent Radiol. 2005;28:313–8.CrossRefPubMed

14.

Maluccio M, Covey AM, Gandhi R, et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol. 2005;16:955–61.PubMed

15.

Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (Baltimore, Md). 1998;27:1578–83.

16.

Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30(1):6–25.

17.

Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer. 1994;74:2449–53.CrossRefPubMed

18.

Kawai S, Okamura J, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison of lipiodol–transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1992;31(Suppl):S1–6.CrossRefPubMed

19.

Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. (in press), 24 Nov 2009 [Epub ahead of print].

20.

Maluccio MA, Covey AM, Porat LB, et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2008;19:862–9.CrossRefPubMed

21.

Bonomo G, Pedicini V, Monfardini L, et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. (in press), 3 Dec 2009 [Epub ahead of print].

22.

Covey AM, Maluccio MA, Schubert J, et al. Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. Cancer. 2006;106:2181–9.CrossRefPubMed

23.

Yamada R, Nakatsuka H, Nakamura K, et al. Hepatic artery embolization in 32 patients with unresectable hepatoma. Osaka City Med J. 1980;26:81–96.PubMed

24.

Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983;148:397–401.PubMed

25.

Nakakuma K, Tashiro S, Hiraoka T, et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer. 1983;52:2193–200.CrossRefPubMed

26.

Konno T, Maeda H, Iwai K, et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol. 1983;19:1053–65.CrossRefPubMed

27.

Clouse ME, Perry L, Stuart K, Stokes KR. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion. 1994;55(Suppl 3):92–7.CrossRefPubMed

28.

Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology. 127(5 Suppl 1):S179–88.CrossRefPubMed

29.

Terayama N, Matsui O, Gabata T, et al. Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization. Cardiovasc Intervent Radiol. 2001;24:383–7.CrossRefPubMed

30.

Bhattacharya S, Dhillon AP, Winslet MC, et al. Human liver cancer cells and endothelial cells incorporate iodised oil. Br J Cancer. 1996;73:877–81.PubMed

31.

Bhattacharya S, Novell JR, Winslet MC, Hobbs KE. Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg. 1994;81:1563–71.CrossRefPubMed

32.

Groupe d’Etude et de Traitement du Carcinome H. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 1995;332:1256–61.

33.

Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.CrossRefPubMed

34.

Aoki T, Imamura H, Hasegawa K, et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg. 2004;139:766–74.CrossRefPubMed

35.

Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–17.CrossRefPubMed

36.

Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol. 2004;7:431–41.CrossRefPubMed

37.

Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461–9.CrossRefPubMed

38.

Livraghi T, Meloni F, Morabito A, Vettori C. Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl. 2004;10(2 Suppl 1):S98–106.CrossRefPubMed

39.

Georgiades CS, Liapi E, Frangakis C, et al. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol. 2006;17:1619–24.CrossRefPubMed

40.

Liapi E, Lee KH, Georgiades CC, Hong K, Geschwind JF. Drug-eluting particles for interventional pharmacology. Tech Vasc Interv Radiol. 2007;10:261–9.CrossRefPubMed

41.

Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol. 2007;25:978–86.CrossRefPubMed

42.

Liapi E, Georgiades CC, Hong K, Geschwind JF. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol. 2007;10:2–11.CrossRefPubMed

43.

Kamel IR, Liapi E, Reyes DK, et al. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009;250:466–73.CrossRefPubMed

44.

Hong K, Liapi E, Georgiades CS, Geschwind JF. Case-controlled comparison of a percutaneous collagen arteriotomy closure device versus manual compression after liver chemoembolization. J Vasc Interv Radiol. 2005;16:339–45.PubMed

45.

Georgiades CS, Hong K, D’Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2005;16:1653–9.PubMed

46.

de Luis E, Bilbao J, de Ciércoles J, et al. In vivo evaluation of a new embolic spherical particle (HepaSphere) in a kidney animal model. Cardiovasc Intervent Radiol. 2008;31:367–76.CrossRefPubMed

47.

Poon RT, Tso WK, Pang RW, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol. 2007;5:1100–8.CrossRefPubMed

48.

Constantin M, Fundueanu G, Bortolotti F, et al. Preparation and characterisation of poly(vinyl alcohol)/cyclodextrin microspheres as matrix for inclusion and separation of drugs. Int J Pharmaceutics. 2004;285:87–96.CrossRef

49.

Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–81.CrossRefPubMed

50.

Malagari K, Chatzimichael K, Alexopoulou E, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol. 2008;31:269–80.CrossRefPubMed

51.

Vossen JA, Reyes DK, Kamel IR, et al. Single centre phase II trial of transarterial chemoembolization with drug eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the USA. Presented at: CIRSE; Lisbon, Portugal; 2009.

52.

Reyes DK, Geschwind JF, Wahlin T, et al. Intraarterial doxorubicin-eluting microspheres for patients with unresectable hepatocellular carcinoma: a pilot study. Presented at: CIRSE; Athens, Greece; 2007.

53.

Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.CrossRefPubMed

54.

Massa Saluzzo C, Vignali C, Nicolini A, et al. TACE with HepaSphere microspheres loaded with chemotherapeutic agent: early experience in Italy of a multi-centre study. Presented at: World Conference in Interventional Oncology (WCIO); Washington, DC; 2007.

55.

Ha BY, Ahmed A, Sze DY, et al. Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. Aliment Pharmacol Ther. 2007;26:839–46.CrossRefPubMed

56.

Kim P, Prapong W, Sze DY, So SK, Razavi MK. Treatment of hepatocellular carcinoma with sub-selective transcatheter arterial oily chemoinfusion. Tech Vasc Interv Radiol. 2002;5(3):127–31.

57.

Kim JH, Yoon HK, Kim SY, et al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther. 2009;29:1291–8.CrossRefPubMed

58.

De Luna W, Sze DY, Ahmed A, et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant. 2009;9:1158–68.CrossRefPubMed

59.

Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic ⁹⁰Y-microspheres. J Nucl Med. 2000;41:1673–81.PubMed

60.

Dawson LA. Hepatic arterial yttrium 90 microspheres: another treatment option for hepatocellular carcinoma. J Vasc Interv Radiol. 2005;16:161–4.PubMed

61.

Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552–63.PubMed

62.

Yorke ED, Jackson A, Fox RA, Wessels BW, Gray BN. Can current models explain the lack of liver complications in Y-90 microsphere therapy? Clin Cancer Res. 1999;5(10 Suppl):3024s–30s.PubMed

63.

Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18:2210–8.PubMed

64.

Dawson LA, McGinn CJ, Lawrence TS. Conformal chemoradiation for primary and metastatic liver malignancies. Semin Surg Oncol. 2003;21:249–55.CrossRefPubMed

65.

Ariel IM. Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (Y90 radiating microspheres). Ann Surg. 1965;162:267–78.CrossRefPubMed

66.

Ariel IM, Pack GT. Treatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapy. Cancer. 1967;20:793–804.CrossRefPubMed

67.

Blanchard RJ, Grotenhuis I, Lafave JW, Frye CW, Perry JF Jr. Treatment of experimental tumors; utilization of radioactive microspheres. Arch Surg. 1964;89:406–10.PubMed

68.

Nolan TR, Grady ED. Intravascular particulate radioisotope therapy: clinical observations of 76 patients with advanced cancer treated with 90-yttrium particles. Am Surgeon. 1969;35:181–8.PubMed

69.

Lau WY, Ho S, Leung WT, et al. What determines survival duration in hepatocellular carcinoma treated with intraarterial yttrium-90 microspheres? Hepatogastroenterology. 2001;48:338–40.PubMed

70.

Carr BI. Hepatic arterial ⁹⁰yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004;10(2 Suppl 1):S107–10.CrossRefPubMed

71.

Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S194–205.CrossRefPubMed

72.

Herba MJ, Thirlwell MP. Radioembolization for hepatic metastases. Semin Oncol. 2002;29:152–9.CrossRefPubMed

73.

Herba MJ, Illescas FF, Thirlwell MP, et al. Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology. 1988;169:311–4.PubMed

74.

Andrews JC, Walker SC, Ackermann RJ, et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med. 1994;35:1637–44.PubMed

75.

Campbell AM, Bailey IH, Burton MA. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol. 2000:1023–33.

76.

Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52–64.CrossRefPubMed

77.

Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16(2 Pt 1):195–203.

78.

Lewandowski RJ, Thurston KG, Goin JE, et al. ⁹⁰Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135–150 Gy as measured by [¹⁸F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol. 2005;16:1641–51.PubMed

79.

Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of ⁹⁰Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627–39.PubMed

80.

Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere(R)) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol. 2006;94:572–86.CrossRefPubMed

81.

Kulik LM, Mulcahy MF, Hunter RD, et al. Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl. 2005;11:1127–31.CrossRefPubMed

82.

Tancredi T, McCuskey PA, Kan Z, Wallace S. Changes in rat liver microcirculation after experimental hepatic arterial embolization: comparison of different embolic agents. Radiology. 1999;211:177–81.PubMed

83.

Geschwind JF, Artemov D, Abraham S, et al. Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol. 2000;11:1245–55.CrossRefPubMed

84.

Boucher E, Bouguen G, Garin E, et al. Adjuvant intraarterial injection of ¹³¹I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up. J Nucl Med. 2008;49:362–6.CrossRefPubMed

85.

Borbath I, Lhommel R, Bittich L, et al. ¹³¹I-labelled-iodized oil for palliative treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2005;17:905–10.CrossRefPubMed

86.

Carr BI. Hepatocellular carcinoma: Current management and future trends. Gastroenterology. 2004;127:S218.CrossRefPubMed

87.

Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13(9 Pt 2):S223–9.CrossRefPubMed

88.

Foubister V. Energy blocker to treat liver cancer. Drug Discovery Today. 2002;7:934.CrossRefPubMed

89.

Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002;62:6070–9.PubMed

90.

Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 2001;8:1618–26.CrossRefPubMed

91.

Yang W, Chen MH, Wang MQ, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res. 2009;39:231–40.CrossRefPubMed

92.

Reyes DK, Vossen JA, Kamel IR, et al. Phase II trial of bevacizumab combined with transarterial chemoembolization (TACE) for hepatocellular carcinoma: initial experience at two institutions. ASCO 2010 Gastrointestinal Cancers Symposium, Orlando, FL; 2010.

93.

Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54.CrossRefPubMed

94.

Yuen MF, Chan AOO, Wong BCY, et al. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol. 2003;98:1181–5.PubMed

95.

Brown DB, Chapman WC, Cook RD, et al. Chemoembolization of hepatocellular carcinoma: patient status at presentation and outcome over 15 years at a single center. Am J Roentgenol. 2008;190:608–15.CrossRef

96.

Liapi E, Lee KH, Hong K, et al. Chemoembolization of hepatocellular carcinoma with a standardized treatment and follow-up protocol: survival, clinical, and tumor control outcome over 11 years at a single center. Presented at: 94th Scientific Assembly and Meeting, Radiologic Society of North America; Chicago, IL; 2008.

97.

Malagari K, Alexopoulou E, Chatzimichail K, et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging. 2008;33:512–9.CrossRefPubMed

98.

Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. Cancer. 2009;115:616–23.CrossRefPubMed

99.

Kettenbach J, Stadler A, Katzler IV, et al. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol. 2008;31:468–76.CrossRefPubMed

100.

Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of ⁹⁰Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71–81.CrossRefPubMed

101.

Grosso M, Vignali C, Quaretti P, et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol. 2008;31(6):1141–9.

Title: Intra-Arterial Therapies for Hepatocellular Carcinoma: Where Do We Stand?
Authors: Eleni Liapi, MD
Jean-Francois H. Geschwind, MD
Publication date: 01-05-2010
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 5/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-010-0977-4

At a glance: The STEP trials

Springer Medicine

Intra-Arterial Therapies for Hepatocellular Carcinoma: Where Do We Stand?

Abstract

Purpose and Design

Results and Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose and Design

Results and Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2010

Anterior Perineal PlanE for Ultralow Anterior Resection of the Rectum (The APPEAR Technique): A Video Demonstration

Emerging Therapeutic Approaches to Hepatocellular Carcinoma

Critical Assessment of Risk Factors for Complications After Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei

KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications

Postoperative Pancreatic Fistula After Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: Incidence, Risk Factors, Management, and Clinical Sequelae

EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer